Because of advances in automation, human genomic sequences are being deposited in public databases at a dramatic rate. However, the process of detecting genes in these sequences is still something of an art. Here we describe the implementation and testing of a relatively straightforward computational approach, the Virtual Transcribed Sequence project, which analyzes their gene content using the gene prediction program GENSCAN (GENSCAN 1.0 1,2) in combination with similarity-based methods. This approach identifies many novel human genes not found even in EST databases.
Experimental tests performed on a sample of predicted ORFs not similar to known genes detected spliced transcripts of the appropriate size and sequence in approximately 50% of cases, similar to the proportion of spliced transcripts detected for a sample of predicted ORFs with significant similarity to known genes. These results suggest that a large majority of predicted ORFs correspond to expressed genes and that a substantial fraction of human genes remain absent from EST databases but are detectable by computational approaches.
MATERIALS AND METHODS
Human genome sequences source. Portions of GenBank Release 112 were used, including all of the Homo sapiens Genome Survey Sequence (GSS) and high throughput genomic sequencing (HTG) entries, and entries from the primate flatfiles described as DNA in the LOCUS record. We used the following web pages: the Lawrence Berkeley National Laboratory Human Genome Center (USA) (http:// www-hgc.lbl.gov/); the Whitehead Institute/MIT Genome Sequencing Project (USA) (http://www-seq.wi.mit.edu/); the Genome Therapeutics Corporation (USA) (http://www.genomecorp.com/); and the Yale Center for Medical Informatics (USA) (http://paella.med. yale.edu/). We also accessed the FTP sites of the Sanger Centre (UK) (http://www.sanger.ac.uk/), the Washington University Genome Sequencing Center (USA) (http://genome.wustl.edu/gsc/), and the Japan Science and Technology Corporation (http://www-alis.tokyo. jst.go.jp/).
RepeatMaker parameters. RepeatMaker was run with the '-l' option which causes masking of interspersed repeats, but not low complexity DNA or simple repeats, since these regions sometimes correspond to portions of exons.
WU-BLAST parameters. WU-BLAST was run with the following parameters: S ϭ 170, S2 ϭ 150, M ϭ 5, N ϭ Ϫ11, Q ϭ 11, R ϭ 11, -filter sequence.
GENEMATCHER parameters. GENEMATCHER (swp) was run with the following parameters: threshold ϭ 20, summaries ϭ 20, alignments ϭ 20.
RT-PCR analysis. For amplification of a segment of VTS, reverse transcription, and PCR(RT-PCR) were performed as previously described (14) using primers flanking a predicted intron with Takara RNA LA PCR kit (Kyoto, Japan), according to the manufacturer's protocol. Briefly, after reverse transcription of 10 ng each of the various human tissue RNAs by AMV reverse transcriptase, 40 cycles of PCR were performed with LA Taq, a high efficiency polymerase enzyme mixture. The resultant PCR products were analyzed on a 2% (w/v) agarose gel. Excision of each putative intron was confirmed by BigDye terminator DNA sequencing method (Perkin-Elmer, CA).
RESULTS
Obtaining human genome sequences. Our strategy is summarized in Fig. 1 . Human genomic sequences were obtained from Release 112 of the GenBank sequence database (4) and from the web pages and FTP sites listed in the figure legend. The final set of 710,275 sequence entries, 88.7% from GenBank and 11.3% from web and FTP sites, totaled 1,082,568,823 base pairs (bp), representing approximately 700 megabases (Mbp) of the human genome, or about 25% of the total, after correcting for redundancy as discussed below.
Extracting VTS sequences from human genome sequences. Our initial approach was to first mask (eliminate) repetitive elements from the genomic sequences using RepeatMasker (RepeatMasker042199 3, http:// ftp.genome.washington.edu/RM/RepeatMasker.html), but because this program takes about 30 min to run on a typical 100 kb genomic entry on our Sun Enterprise 4000 computer, this step would have taken almost a year to complete. Instead, we chose to initially run GENSCAN (approximately 65 times faster than RepeatMasker) on all the unmasked genomic sequences to identify putative gene-containing entries and then to run RepeatMasker on this subset of sequences (approximately 6.1% of the total), followed by a second run of GENSCAN on the masked sequences to obtain putative ORFs. Subsequently, E. coli and vector sequences were identified and eliminated using cross-match (Green, P. http://www.phrap.org/). Predicted ORFs less than 150 bp in length (coding for fewer than 50 amino acids) were also discarded, as were ORFs consisting of only a single exon, since these may often correspond to processed pseudogenes. This procedure yielded a total of 28,192 putative multi-exon genes, with some redundancy resulting from duplications and overlaps in the input genomic sequences. To reduce this redundancy, an all-against-all comparison of the putative transcribed sequences was performed using WU-BLAST (Gish, W. http://blast.wustl.edu/). Putative transcribed sequences with BLAST probability (P-values) of less than 1e-60 which were more than 95% identical, or with P-values less than 1e-20 and more than 98% identical, were grouped into clusters. This process placed the 28,192 sequences into 18,269 groups. These nonredundant putative gene sequences are termed human Virtual Transcribed Sequences (VTS).
Clustering of VTS sequences. The average size of VTS ORFs is 193 amino acids (AA). Of the VTS sequences, 98 ORFs are longer than 2000 amino acids, and the longest one of these is 5918 AA. The total lengths of the unclustered and clustered VTS sequences were 21.57 Mbp and 14.25 Mbp, respectively. Since the redundancy of the unclustered putative genes reflects the redundancy in the underlying genomic sequences, we can estimate that the proportion of the human genome which has been analysed in the present study is about: 1,083 Mbp ϫ 14.25/21.57 ϭ 715 MB, or approximately 25% of the genome. Some of the data collected are at a very preliminary stage of sequencing, not yet assembled with dozens of contigs randomly concatenated. Specifically, a total of 3,447 VTSs derive from 1177 GenBank sequences described as 'unordered pieces'. Assuming that the predicted genes/gene fragments from such a set of unordered pieces often represent just a single gene, a more conservative estimate of the number of non-redundant genes identified is: 18,278 Ϫ (3,447-1,177) ϭ 16,008.
Comparing VTS proteins with known proteins.
In order to identify genes identical or homologous to known genes among the VTS sequences, similarity searches were performed against the OWL nonredundant protein database, release number 31.4 (The University of Leeds at http://bmbsgi11.leeds.ac.uk/ bmb5dp/homeowl.html) using BLAST (5) as well as Smith-Waterman alignment (6) performed by the GENEMATCHER software (http://www.paracel.com/), using the BLOSUM62 amino acid similarity matrix (7), with the conceptually translated VTS peptides as queries. The results of the BLAST searches were used to classify the VTS sequences as follows:
(A) 'Known human gene' if Species ϭ Homo sapiens AND P Ͻϭ 1e-40 AND Ͼϭ 75% identities AND (Number of (Positives-Identities)) Ͻϭ 4% of (Number of Identities) OR Identities ϭ 100% AND Length of contiguous identities Ͼϭ 30 amino acids.
(B) 'Known in another species' if the criteria of (A) are met, but the species is not Homo sapiens.
(C) 'Related' if the criteria of (A) and (B) are not met, but the P-value of the strongest BLAST hit is less than 1e-6.
(D) 'Unknown' if none of (A), (B), (C) apply.
This classification was further refined by comparing the "unknown" and "related" VTS DNA sequences with human mRNA entries from GenBank using GENEMATCHER (6) . VTS sequences with similarity to a known human mRNA with (P Ͻϭ 1e-60 AND Identities Ͼ 95%) OR (P Ͻϭ 1e-20 AND Identities Ͼ 98%) were reclassified as 'known'. Using these criteria, we found that approximately 30% of VTS ORFs can be classified as 'known human genes', 1-2% as 'known in another species', 20% as 'related', but fully 48% of the total are classified as 'unknown'.
RT-PCR experiments to verify the validity of VTS genes.
To determine whether these 'unknown' ORFs correspond primarily to real genes or to GENSCAN false positives, the reverse transcription polymerase chain reaction (RT-PCR) method was used to test for expression/splicing of two groups of VTS sequences. First, a group of 128 VTS ORFs was chosen which show significant homology with at least one protein from the OWL database, but which lack identity with any OWL or EST entry (8) . Second, a set of 116 VTSs which lack significant similarity to any OWL or EST sequence (as of June, 1999) was tested. The results of RT-PCR tests for the 244 VTS sequences described above, using human mRNA samples from 86 tissues and cell cultures are summarized in Table 1 . Figure 2 illustrates typical RT-PCR results for several VTS sequences. All of the primer pairs for RT-PCR were designed with one or more intervening predicted introns so that a band of a characteristic size would result if the gene was expressed and spliced as predicted by GENSCAN. A substantial fraction of the obtained RT-PCR products were directly sequenced to confirm the splicing pattern of the intron(s). In 100% of cases (41 out of 41) where a single band of the expected size was observed and sequenced, the predicted intron was confirmed. Even when multiple bands or a band with a somewhat different size was observed, the predicted intron was confirmed in 67% of cases (20 out of 30), suggesting that the majority of examples in this class also represent expressed genes, but may often correspond to incomplete or partially accurate GENSCAN predictions and/or alternative splicing. For the group which possessed homology to an OWL sequence, the estimated proportion of confirmed genes detectable by RT-PCR (see Table 1 ) was: (36 (41/41) ϩ 45 (20/30))/128 ϭ 52%. The corresponding value for the group with no significant homology to known proteins or ESTs is: (32 (41/41) ϩ 41 (20/30))/116 ϭ 51%.
To our knowledge, these data represent the first large scale, systematic experimental test of the accuracy of GENSCAN. If one assumes that substantially all of the first group of VTS sequences which are homologous to a known protein are real (but perhaps have unusual properties making them difficult to clone such as low expression level or lack of polyadenylation), then the fraction 52% would represent essentially the sensitivity of the RT-PCR method, i.e., the false negative rate of this detection method is likely to be about one half. This assumption is reasonable because the report of human chromosome 22 (9) estimated that GENSCAN detected at least partially 94% of all annotated genes in the chromosome. In this context, the fact that the proportion of RT-PCR-confirmed genes in the second group, for which no homolog is known, is not significantly lower (51%) suggests that the rate of GENSCAN false positives is relatively low, although it may be premature to try to assign a precise Note. Reverse transcription and PCR were performed as previously described (18) using primers for amplification of a segment of VTS. The resultant PCR products were analyzed on a 2% (w/v) agarose gel and their sequences were confirmed by BigDye terminator sequencing method (Perkin-Elmer, CA). Sample calculation of number of verifiable genes for class with significant OWL homology. numerical value at this time. This argument suggests that VTS approach may mine many unknown genes not yet cataloged even in the EST database. 9000 (48% of all) VTS ORFs are 'unknown' as shown above and 21.0% of the unknown VTSs do not match any ESTs as described below. In the report of human chromosome 22 (9), 325 out of 817 genes detected by GENSCAN are not hit by both OWL protein database and EST, and they presume that 100 out of such 325 virtual genes are real.
Comparing VTS sequences with EST sequences.
The genome research community routinely use ESTs as "gene tags," and current publicly available EST databases are reported to contain a substantial fraction (approximately 72%) of expressed human mRNAs (10), so it was of obvious interest to examine the relationship between EST and VTS sequences. We compared all of the VTS DNA sequences with Genbank dbEST sequences using BLASTN (5) . VTS sequences with similarity to EST sequences with (P Ͻϭ 1e-60 AND identities Ͼϭ 95% AND match length Ͼϭ 50 bp) OR (P Ͻϭ 1e-20 AND identities Ͼϭ 98% AND match length Ͼϭ 50 bp) were classified as "hit." Surprisingly, comparisons of VTS DNA sequences with EST data from GenBank Release 112 revealed that approximately 60% of VTS sequences do not match any known EST. Undoubtedly some of these VTS sequences represent pseudogenes or false GENSCAN predictions, but the above arguments imply that these errors represent a relatively small fraction of VTS sequences, certainly far below 60%, and probably well below the 28% of genes expected to be missing from current EST databases.
We further examined how much fraction of each homology class is hit by EST using the method and criteria described above. The 74.3% (4242/5706) of class A, 58.7% (145/247) of class B, 41.2% (1401/3399) of C, and 1.33% (118/8917) of class D are detected to be hit by EST, so the 12.3% ((1401 ϩ 118)/(3399 ϩ 8917)) of unknown genes (class C ϩ D) are hit by EST. Therefore, we interpret these data as implying that current EST databases may be systematically missing significant portions of the human gene complement. This situation could arise either because a large fraction of genes have very rare and/or tissue-limited patterns of expression and are thus difficult to clone, or because of other properties. For example, almost all cDNA libraries used for EST sequencing derive from polyAϩ RNAs, but there is indirect evidence that a substantial fraction of human genes may not undergo polyadenylation (11, 12) . As a consequence, the number of distinct human genes represented in EST databases may now be approaching the saturation point of this method. However, the data described here suggest that the detection of novel genes by genome sequencing combined with specific computational approaches-principally gene prediction and protein sequence similarity methodsand experimental methods such as RT-PCR, Northern blotting, etc. is likely to continue at a rapid rate. Genetic linkage studies will help to identify the functions of some of these genes, particularly those that are involved in important human diseases. Although cDNA clones of genes discovered in this manner will be more difficult to isolate, methods such as long distance RT-PCR using primers designed from VTS sequences, artificial synthesis of cDNA deduced from VTS sequences, or direct peptide synthesis should eventually permit studies of gene function to be carried out.
FIG. 2.
RT-PCR detection of predicted spliced products. A sample of the results of RT-PCR experiments to test for the expression of predicted spliced products is shown. Six VTS sequences lacking matches to EST sequences (VTS00455, VTS00527, VTS29413, VTS33181, VTS34233 and VTS35540 from the top panel to the bottom) were selected and amplified by RT-PCR using primers flanking a predicted intron using 10 ng each of the various human tissue RNAs. The RT-PCR experiments were performed using Takara RNA LA PCR kit (Kyoto, Japan), according to the manufacturer's protocol. Briefly, after reverse transcription by AMV reverse transcriptase, 40 cycles of PCR were performed with LA Taq, a high efficiency polymerase enzyme mixture. The band sizes showed good agreement with the expected size for each VTS sequence shown. Excision of each putative intron was confirmed by DNA sequencing.
FIG. 3.
Examples of putative new domains/gene families. Sequence alignments of conceptually translated VTS ORFs which illustrate probable new domains or gene families are illustrated. Identical amino acids are shown in black and marked with an asterisk; similar residues are shown in gray and marked with a dot. The locations of introns relative to the coding regions in the two sequences are indicated by arrows above or below the sequences, respectively. Adjacent to each arrow are numbers indicating the length of the intron in bp and, in parentheses, the 'phase' of each intron. The standard convention is used: An intron located between codons is considered phase zero; after the first base of a codon, phase 1; and after the second base of a codon, phase 2.
Comparing VTS proteins with S. cerevisiae and C. elegans proteins. We further compared VTS ORF sequences with the database of S. cerevisiae proteins (October, 1996) at (http://www-genome.stanford.edu/) and the C. elegans protein database (October, 1998) from (http://www.sanger.ac.uk/). Many translated VTS ORFs match putative proteins from yeast and/or nematodes. Significant protein sequence similarity between such distantly related species provides strong prima facie evidence that both the VTS and related yeast and/or nematode ORFs correspond to real genes.
New gene families, new subfamilies, and new domains.
Moreover, by comparing all of the unknown VTS ORFs with each other, several probable new gene families or functional domains were identified. Specifically, we found three pairs of VTS ORFs which appear to represent new gene families in the sense that they are very similar to each other (GENEMATCHER (swp) E-value Ͻ 1e-120) but have no significant similarity to any known protein (no homolog detected by BLAST and GENEMATCHER). Seven additional pairs of VTS ORFs appear to represent new gene subfamilies in that they are highly similar to each other (P Ͻ 1e-40), but only moderately similar to known proteins (most significant BLAST hit in OWL database between 1e-40 and 1e-6). Finally, three pairs of VTS ORFs appear to represent novel protein domains in that the ORFs are similar to known proteins in one region, but also have strong similarity to each other in a region which is not similar to any known protein. An example of the gene families, new subfamilies and new domains are given in Figs. 3a, 3b , and 3c. Further evidence supporting the validity of these genes and the accuracy of the GENSCAN predictions comes from the conserved locations and phases of introns in these regions (see Fig. 3 ).
DISCUSSION
Using our approach, we expect to detect new genes far more sensitive than EST method, especially for rarely expressed ones. It is believed that the exon prediction accuracy is strongly depending on both the base-call error and natural frame shift (13), but because sequences of various sources are used in constructing VTSs, it is quite hard to estimate how these factors affect the prediction of genes. We proved that about half of the gene candidates that are not hit by ESTs can be detected, suggesting that our method will be useful to detect new genes that are difficult to be found by EST methods. On top of that, we clearly demonstrated that the false positive rate of GENSCAN should be quite low. We expect that the current VTS project and future developments of it will serve as a useful resource for the human genome project.
